Response rate as an endpoint in clinical trials.
Publication
, Journal Article
George, SL
Published in: J Natl Cancer Inst
January 17, 2007
Duke Scholars
Published In
J Natl Cancer Inst
DOI
EISSN
1460-2105
Publication Date
January 17, 2007
Volume
99
Issue
2
Start / End Page
98 / 99
Location
United States
Related Subject Headings
- Treatment Outcome
- Randomized Controlled Trials as Topic
- Osteosarcoma
- Oncology & Carcinogenesis
- Multicenter Studies as Topic
- Humans
- Europe
- Drug Administration Schedule
- Dose-Response Relationship, Drug
- Disease-Free Survival
Citation
APA
Chicago
ICMJE
MLA
NLM
George, S. L. (2007). Response rate as an endpoint in clinical trials. J Natl Cancer Inst, 99(2), 98–99. https://doi.org/10.1093/jnci/djk024
George, Stephen L. “Response rate as an endpoint in clinical trials.” J Natl Cancer Inst 99, no. 2 (January 17, 2007): 98–99. https://doi.org/10.1093/jnci/djk024.
George SL. Response rate as an endpoint in clinical trials. J Natl Cancer Inst. 2007 Jan 17;99(2):98–9.
George, Stephen L. “Response rate as an endpoint in clinical trials.” J Natl Cancer Inst, vol. 99, no. 2, Jan. 2007, pp. 98–99. Pubmed, doi:10.1093/jnci/djk024.
George SL. Response rate as an endpoint in clinical trials. J Natl Cancer Inst. 2007 Jan 17;99(2):98–99.
Published In
J Natl Cancer Inst
DOI
EISSN
1460-2105
Publication Date
January 17, 2007
Volume
99
Issue
2
Start / End Page
98 / 99
Location
United States
Related Subject Headings
- Treatment Outcome
- Randomized Controlled Trials as Topic
- Osteosarcoma
- Oncology & Carcinogenesis
- Multicenter Studies as Topic
- Humans
- Europe
- Drug Administration Schedule
- Dose-Response Relationship, Drug
- Disease-Free Survival